Insulin resistance is a central component of the metabolic dysregulation observed in obesity, which puts one at risk for the development of type 2 diabetes and complications related to diabetes such as chronic kidney disease. Insulin resistance and compensatory hyperinsulinemia place one at risk for other risk factors such as dyslipidemia, hypertension, and proteinuria, e.g., development of kidney disease. Our traditional view of insulin actions focuses on insulin-sensitive tissues such as skeletal muscle, liver, adipose tissue, and the pancreas. However, insulin also has distinct actions in kidney tissue that regulate growth, hypertrophy, as well as microcirculatory and fibrotic pathways which, in turn, impact glomerular filtration, including that governed by tubuloglomerular feedback. However, it is often difficult to discern the distinct effects of excess circulating insulin and impaired insulin actions, as exist in the insulin resistance individual, from the associated effects of obesity or elevated systolic blood pressure on the development and progression of kidney disease over time. Therefore, we review the experimental and clinical evidence for the distinct impact of insulin resistance on kidney function and disease.

1.
Chen J, Muntner P, Hamm LL, et al: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004;140:167-174.
2.
Yamagata K, Ishida K, Sairenchi T, et al: Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007;71:159-166.
3.
Soltani Z, Washco V, Morse S, Reisin E: The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches. Curr Hypertens Rep 2015;17:7.
4.
Pulakat L, DeMarco VG, Whaley-Connell A, Sowers JR: The impact of overnutrition on insulin metabolic signaling in the heart and the kidney. Cardiorenal Med 2011;1:102-112.
5.
Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR: Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 2013;62:1543-1552.
6.
Ferdinand KC, Rodriguez F, Nasser SA, et al: Cardiorenal metabolic syndrome and cardiometabolic risks in minority populations. Cardiorenal Med 2014;4:1-11.
7.
Zhan, J, Bottiglieri T, McCullough PA: The central role of endothelial dysfunction in cardiorenal syndrome. Cardiorenal Med 2017;7:104-117.
8.
Shepard PR, Kahn BB: Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus. N Engl J Med 1999;341:248-257.
9.
Muniyappa R, Sowers JR: Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 2013;14:5-12.
10.
Nistala R, Whaley-Connell A: Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II. Mol Cell Endocrinol 2013;378:53-58.
11.
Marmy-Conus N, Hannan KM, Pearson RB: Ro 31-6045, the inactive analogue of the protein kinase C inhibitor Ro 31-8220, blocks in vivo activation of p70(s6k)/p85(s6k): implications for the analysis of S6K signalling. FEBS Lett 2002;519:135-140.
12.
Bhandari BK, Feliers D, Duraisamy S, et al: Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells. Kidney Int 2001;59:866-875.
13.
Coward RJ, Welsh GI, Yang J, et al: The human glomerular podocyte is a novel target for insulin action. Diabetes 2005;54:3095-3102.
14.
Das F, Dey N, Bera A, et al: MicroRNA-214 reduces insulin-like growth factor-1 (IGF-1) receptor expression and downstream mTORC1 signaling in renal carcinoma cells. J Biol Chem 2016;291:14662-14676.
15.
Brosius FC, Coward RJ: Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv Chronic Kidney Dis 2014;21:304-310.
16.
Chiu T, Santiskulvong C, Rozengurt E: EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway. Am J Physiol Gastrointest Liver Physiol 2005;288:G182-G194.
17.
Chen JK, Chen J, Thomas G, et al: S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2009;297:F585-F593.
18.
Yamakawa T, Tanaka S, Kamei J, et al: Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells. Eur J Pharmacol 2003;478:39-46.
19.
Oroszlan M, Bieri M, Ligeti N, et al: Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 2010;23:125-132.
20.
Whaley-Connell AT, Habibi J, Nistala R, et al: Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. Am J Nephrol 2012;35:90-100.
21.
Whaley-Connell A, Habibi J, Panfili Z, et al: Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol 2011;34:115-125.
22.
Jia G, Aroor AR, Sowers JR: Arterial stiffness: a nexus between cardiac and renal disease. Cardiorenal Med 2014;4:60-71.
23.
Aziz F, Chaudhary K: The triad of sleep apnea, hypertension, and chronic kidney disease: a spectrum of common pathology. Cardiorenal Med 2017;7:74-82.
24.
Muniyappa R, Sowers JR: Endothelial insulin and IGF-1 receptors: when yes means NO. Diabetes 2012;61:2225-2227.
25.
Rocchini AP, Marker P, Cervenka T: Time course of insulin resistance associated with feeding dogs a high-fat diet. Am J Physiol 1997;272:E147-E154.
26.
Pandey G, Makhija E, George N, et al: Insulin regulates nitric oxide production in the kidney collecting duct cells. J Biol Chem 2015;290:5582-5591.
27.
Manhiani MM, Cormican M, Brands MW: Chronic sodium-retaining action of insulin in diabetic dogs. Am J Physiol Renal Physiol 2011;300:F957-F965.
28.
Bell TD, DiBona GF, Biemiller R, Brands MW: Continuously measured renal blood flow does not increase in diabetes if nitric oxide synthesis is blocked. Am J Physiol Renal Physiol 2008;295:F1449-F1456.
29.
Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;98:894-898.
30.
Kocyigit I, Taheri S, Sener EF, et al: Endothelial nitric oxide synthase gene expression is associated with hypertension in autosomal dominant polycystic kidney disease. Cardiorenal Med 2014;4:269-279.
31.
DeFronzo RA, Alvestrand A, Smith D, et al: Insulin resistance in uremia. J Clin Invest 1981;67:563-568.
32.
Landau M, Kurella-Tamura M, Shlipak MG, et al: Correlates of insulin resistance in older individuals with and without kidney disease. Nephrol Dial Transplant 2011;26:2814-2819.
33.
Becker B, Kronenberg F, Kielstein JT, et al: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005;16:1091-1098.
34.
Shinohara K, Shoji T, Emoto M, et al: Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002;13:1894-1900.
35.
Fliser D, Pacini G, Engelleiter R, et al: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998;53:1343-1347.
36.
Kobayashi S, Maesato K, Moriya H, et al: Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005;45:275-280.
37.
Emoto M, Nishizawa Y, Maekawa K, et al: Insulin resistance in non-obese, non-insulin-dependent diabetic patients with diabetic nephropathy. Metabolism 1997;46:1013-1018.
38.
Mykkanen L, Zaccaro DJ, Wagenknecht LE, et al: Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998;47:793-800.
39.
Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, He J: Insulin resistance and risk of chronic kidney disease in non-diabetic US adults. J Am Soc Nephrol 2003;14:469-477.
40.
Whaley-Connell A, Pavey BS, McCullough PA, Saab G, Li S, McFarlane SI, Chen SC, Vassalotti JA, Collins AJ, Bakris G, Sowers JR; KEEP Investigators: Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich) 2010;12:51-58.
41.
Fox CS, Larson MG, Leip EP, et al: Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844-850.
42.
US Renal Data System: USRDS 2015 Chapter 1: CKD in the General Population.
43.
Kramer HJ, Saranathan A, Luke A, et al: Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006;17:1453-1459.
44.
Iseki K, Ikemiya Y, Kinjo K, et al: Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004;65:1870-1876.
45.
Ejerblad E, Fored MC, Lindblad P, et al: Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006;17:1695-1702.
46.
Park J, Ahmadi SF, Streja E, et al: Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis 2014;56:415-425.
47.
Degoulet P, Legrain M, Réach I, et al: Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982;31:103-110.
48.
Kopple JD, Zhu X, Lew NL, Lowrie EG: Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999;56:1136-1148.
49.
Leavey SF, McCullough K, Hecking E, et al: Body mass index and mortality in “healthier” as compared with “sicker” haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001;16:2386-2394.
50.
Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al: Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 2005;46:489-500.
51.
Zammit AR, Katz MJ, Derby C, Bitzer M, Lipton RB: Metabolic syndrome and smoking are associated with future development of advanced chronic kidney disease in older adults. Cardiorenal Med 2016;6:108-115.
52.
Hsu CY, McCulloch CE, Iribarren C, et al: Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21-28.
53.
Praga M, Hernandez E, Herrero JC, et al: Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000;58:2111-2118.
54.
Pinto-Sietsma SJ, Mulder J, Janssen WM, et al: Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000;133:585-591.
55.
Verhave JC, Hillege HL, Burgerhof JGM, et al: Impact of sodium intake on urinary albumin excretion is enhanced by obesity. J Am Soc Nephrol 2002;13:661-662.
56.
De Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL; PREVEND study group: Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002;26(suppl 4):S21-S24.
57.
Chagnac A, Weinstein T, Korzets A, et al: Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278:F817-F822.
58.
Porter LE, Hollenberg NK: Obesity, salt intake and renal perfusion in healthy humans. Hypertension 1998;32:144-148.
59.
Reisin E, Messerli FG, Ventura HO, Frohlich ED: Renal haemodynamic studies in obesity hypertension. J Hypertens 1987;5:397-400.
60.
Ribstein J, du Cailar G, Mimran A: Combined renal effects of overweight and hypertension. Hypertension 1995;26:610-615.
61.
Chagnac A, Weinstein T, Herman M, et al: The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003;14:1480-1486.
62.
Hall JE: Renal and cardiovascular mechanisms of hypertension. Hypertension 1994;23:381-394.
63.
Obi Y, Kim T, Kovesdy CP, Amin AN, Kalantar-Zadeh K: Current and potential therapeutic strategies for hemodynamic cardiorenal syndrome. Cardiorenal Med 2016;6:83-98.
64.
Jindal A, Brietzke S, Sowers JR: Obesity and the cardiorenal metabolic syndrome: therapeutic modalities and their efficacy in improving cardiovascular and renal risk factors. Cardiorenal Med 2012;2:314-317.
65.
Henegar JR, Bigler SA, Henegar LK, et al: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12:1211-1217.
66.
Kambham N, Markowitz GS, Valeri AM, et al: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-1509.
67.
Wisse BE: The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-2800.
68.
Susic D, Frohlich ED: Hyperuricemia: a biomarker of renal hemodynamic impairment. Cardiorenal Med 2015;5:175-182.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.